https://www.avient.com/sites/default/files/2024-08/LATAM CAI Certifications Bulletin _Portuguese_.pdf
© 2024, All Rights Reserved Avient Corporation https://www.avient.com/company/policies-and-governance-0/global-iso-certificate-library
https://www.avient.com/sites/default/files/2024-04/Maxxam REC Outdoor Plug Socket Case Study_A4.pdf
© 2024, All Rights Reserved Avient Corporation, 33587 Walker Road, Avon Lake, Ohio USA 44012 http://avient.com
https://www.avient.com/sites/default/files/2021-06/sat-avient-de-mexico-sa-de-cv-toluca.pdf
Si desea modificar o corregir sus datos personales, puede acudir a cualquier Módulo de Servicios Tributarios y/o a través de la dirección http://sat.gob.mx "La corrupción tiene consecuencias ¡denúnciala!
https://www.avient.com/industries/consumer/consumer-discretionary/home-household/office-supplies
TPEs that are ideal for healthcare, consumer goods and cutting-edge electronics such as wearables
https://www.avient.com/sites/default/files/2025-04/Supplier Code of Conduct FV_Germ.pdf
Zusätzliche Informationen sind verfügbar unter https://www.cbp.gov/trade/forced-labor. • Behandeln Sie Ihre Mitarbeiter mit Respekt und unterlassen Sie Belästigung oder Diskriminierung von Personen aufgrund von Ethnie, Geschlecht, sexueller Orientierung, Geschlechtsidentität, Alter, Hautfarbe, Religion, nationaler Herkunft, Behinderung, genetischen Informationen, geschütztem Veteranenstatus oder anderen rechtlich geschützten Klassifizierungen. • Tantal, Zinn, Wolfram und Gold oder deren Derivate (3TG-Metalle) sind verantwortungsvoll zu beschaffen.
https://www.avient.com/sites/default/files/2023-05/Mevopur Amber for PET Pharma Pkg Application Bulletin_CN _2.pdf
如需深入了解Mevopur的用途和限制,请参见 HYPERLINK "http://www.avient.com/healthcare-use-limitations-mevopur-products" www.avient.com/healthcareuselimitationsmevopurproducts,或联系您的埃万特销售代表。
https://www.avient.com/sites/default/files/2021-12/avient-sarl-hungary-branch-register-extract-2021-12-07.pdf
Date of registration: 2018/08/21 Published: 2018/08/23 2/4 https://occsz.e-cegjegyzek.hu/IMOnline?
https://www.avient.com/sites/default/files/2025-03/2025 Proxy Statement.pdf
Letter to Shareholders March 27, 2025 Dear Shareholder: You are invited to attend and participate in the Avient Corporation 2025 Annual Meeting of Shareholders (the “Annual Meeting”), which will be held virtually via live webcast at 9:00 a.m.
Please carefully review the proxy materials for the Annual Meeting, which will be held virtually via live webcast on Wednesday, May 14, 2025 at 9:00 a.m.
Attendance and Participation Our Annual Meeting will be conducted on the internet via live webcast.
https://www.avient.com/sites/default/files/2020-11/cotrep-at-20-21-avient-corporation-cesar-ir-pe-94000828.pdf
À Paris, le 17 juillet 2020 1 Disponible sur le site du COTREP : https://www.cotrep.fr/content/uploads/sites/3/2019/02/tri-p1-emballages-sombres-v01-2019.pdf
https://www.avient.com/sites/default/files/resources/POL%2520Gabelli%2520IR%2520Presentation%2520w%2520Non-GAAP%252003%252020%25202014.pdf
Use of Non-GAAP Measures Page 3 PolyOne Commodity to Specialty Transformation Page 4 • Continue specialty transformation • Targeting $2.50 Adjusted EPS by 2015, nearly double 2013 EPS • Drive double digit operating income and adjusted EPS growth • 17 consecutive quarters of double- digit adjusted EPS growth • Shift to faster growing, high margin, less cyclical end markets • Key acquisitions propel current and future growth, as well as margin expansion • Established aggressive 2015 targets • Steve Newlin Appointed, Chairman, President and CEO • New leadership team appointed • Implementation of four pillar strategy • Focus on value based selling, investment in commercial resources and innovation to drive transformation • Volume driven, commodity producer • Heavily tied to cyclical end markets • Performance largely dependent on non- controlling joint ventures 2000-2005 2006 - 2009 2010 – 2013 2014 and beyond -150.00% -50.00% 50.00% 150.00% 250.00% 350.00% PolyOne S&P 500 Russell 2000 Dow Jones Chemical All time high of $38.38 March 7th, 2014 • 17 consecutive quarters of double digit EPS growth • 49% CAGR adjusted EPS expansion 2006-2013 • 2013 stock price increased 73% versus 30% growth in the S&P • More than seven fold increase in market cap: $0.5b $3.6b Strategy and Execution Drive Results Page 5 Appliance 4% Building & Construction 13% Wire & Cable 9% Electrical & Electronics 5% Consumer 10%Packaging 16% Industrial 12% HealthCare 11% Transportation 18% Misc. 2% United States 66% Europe 14% Canada 7% Asia 6% Latin America 7% PP&S 20% Specialty 53% Distribution 27% 0.12 0.27 0.21 0.13 0.68 0.82 1.00 1.31 2.50 $0.00 $0.25 $0.50 $0.75 $1.00 $1.25 $1.50 $1.75 $2.00 $2.25 $2.50 2006 2007 2008 2009 2010 2011 2012 2013 2015 Target Ad ju st ed E ar ni ng s P er S ha re 2013 Revenues: $3.8 Billion End Markets 2013 Revenues: $3.8 Billion EPS Page 6 PolyOne At A Glance Old PolyOne Transformation *Operating Income excludes corporate charges and special items 2% 34% 43% 62% 65- 75% 0% 20% 40% 60% 80% 100% 2005 2008 2010 2013 2015 % o f O pe ra tin g In co m e* JV's Performance Products & Solutions Distribution Specialty Specialty OI $5M $46M $87M $195M Target Mix Shift Highlights Specialty Transformation 2015 Target Page 7 2006 2013 2015 “Where we were” “Where we are” Target 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 12.2% 12 – 16% Global Specialty Engineered Materials 1.1% 9.3% 12 – 16% Designed Structures & Solutions -- 5.6% 8 – 10% Performance Products & Solutions 5.4% 7.2% 9 – 12% Distribution 2.6% 5.9% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 62% 65 – 75% 3) ROIC* (after-tax) 5.0% 9.1% 15% 4) Adjusted EPS Growth N/A 31% Double Digit Expansion Proof of Performance & 2015 Goals *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Page 8 Bridge To $2.50 Adjusted EPS By 2015 2015 EPS: $2.50 2013 EPS: $1.31 Mid single digit revenue CAGR Page 9 Mergers & Acquisitions Spartech accretion Incremental share buybacks Ongoing LSS Programs (50-100 bps/yr) Accelerated Innovation & Mix Improvement Innovation Drives Earnings Growth $20.3 $52.3 2006 2013 Research & Development Spending ($ millions) Specialty Platform Vitality Index Progression* *Percentage of Specialty Platform revenue from products introduced in last five years Page 10 14.3% 30.7% 2006 2013 Specialty Platform Gross Margin % 19.5% 43.0% 2006 2013 Healthcare Consumer Packaging and Additive Technology Transportation Page 11 Unique and Innovative Solutions that Help Customers Win https://www.dropbox.com/sh/dwe4t8aacvhb8ui/uD3p_bdglP/Presentation revise pics/GLS Beverage can closure XO 2.jpg https://www.dropbox.com/sh/dwe4t8aacvhb8ui/-YgkycKypw/Anti-Counterfeiting release & images/GN1979.JPG Net Debt / EBITDA* = 1.8x $48 $317 $600 $0 $100 $200 $300 $400 $500 $600 $700 $800 2015 2020 2023 Significant Debt Maturities As of December 31, 2013 ($ millions) Page 12 Coupon Rates: 7.500% 7.375% 5.250% Debt Maturities & Pension Funding – 12/31/13 *TTM 12/31/2013 ** includes US-qualified plans only 60% 100% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2008 2013 Pension Funding** As of December 31, 2013 Free Cash Flow and Strong Balance Sheet Fund Investment •Targets that expand our: • Specialty offerings •End market presence •Geographic footprint •Operating Margin • Synergy opportunities •Adjacent material solutions •Expanding our sales, marketing, and technical capabilities • Investing in operational and LSS initiatives (including synergy capture) •Manufacturing alignment Organic Growth Share Repurchases Dividends Acquisitions Page 13 $0.16 $0.20 $0.24 $0.32 $0.00 $0.10 $0.20 $0.30 $0.40 2011 2012 2013 2014 Annual Dividend • Repurchased ~5 million shares in 2013 • 15 million shares are available for repurchase under the current authorization The New PolyOne: A Specialty Growth Company 2015 Target: $2.50 Adjusted EPS Why Invest In PolyOne?